Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493705 | 0.87 | MEN1 (0.34) | MEN1GAAKMT2AALDH1A1KDM1A | |
| SCHEMBL313033 | 0.76 | — | — | |
| SCHEMBL4957366 | 0.72 | CHRNB2 (0.34) | — | |
| SCHEMBL1451012 | 0.71 | DRD2 (0.48) | GAAALOX15 | |
| SCHEMBL29144954 | 0.68 | GAA (0.54) | MEN1GAAKMT2AALDH1A1KDM1A | |
| SCHEMBL1162920 | 0.68 | — | — | |
| SCHEMBL123812 | 0.68 | GAA (0.54) | MEN1GAAKMT2AALDH1A1KDM1A | |
| SCHEMBL29408147 | 0.68 | GAA (0.54) | MEN1GAAKMT2AALDH1A1KDM1A | |
| SCHEMBL317969 | 0.68 | GSK3B (0.32) | — | |
| SCHEMBL1384879 | 0.68 | ALDH1A1 (0.37) | MEN1GAAKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020244637-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2020-12-10 | — | — | WO | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-3180006-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-21 | — | — | EP | claimed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | claimed |
| WO-2016023885-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | WO | claimed |
| US-9126998-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | Bayer Pharma AG (DE) | 2015-09-08 | — | — | US | claimed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | claimed |
| WO-2014100021-A1 | TGR5 AGONISTS: IMIDAZOLE AND TRIAZOLE COMPOUNDS CONTAINING A QUATERNARY NITROGEN | EXELIXIS, INC. (US) | 2014-06-26 | — | — | WO | claimed |
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | claimed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | claimed |
| EP-1001762-A1 | METHOD OF USING NEUROTROPHIC CARBAMATES AND UREAS | GPI NIL Holdings, Inc. (US) | 2000-05-24 | — | — | EP | claimed |
| WO-2000010553-A2 | CARBAMATE AND UREA COMPOSITIONS AND NEUROTROPHIC USES | GPI NIL HOLDINGS, INC. (US) | 2000-03-02 | — | — | WO | claimed |
| WO-2000009105-A2 | SMALL MOLECULE CARBAMATES OR UREAS FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| WO-1999062484-A1 | SMALL MOLECULE CARBAMATE OR UREA HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | claimed |
| WO-1999029670-A2 | AMINOCARBONYLTETRALIN AND DIHYDRONAPHTALENE DERIVATES AS THROMBIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-06-17 | — | — | WO | claimed |
| WO-1998037882-A1 | METHOD OF USING NEUROTROPHIC CARBAMATES AND UREAS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-09-03 | — | — | WO | claimed |
| EP-0722449-A1 | BOROPEPTIDE INHIBITORS OF THROMBIN WHICH CONTAIN A SUBSTITUTED PYRROLIDINE RING | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-24 | — | — | EP | claimed |
| WO-1995009859-A1 | BOROPEPTIDE INHIBITORS OF THROMBIN WHICH CONTAIN A SUBSTITUTED PYRROLIDINE RING | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-13 | — | — | WO | claimed |
| US-5294612-A | Hypotensive agents and cardiovascular disorders | STERLING WINTHROP INC. (US) | 1994-03-15 | — | — | US | claimed |
| US-5225207-A | Complexes derived from platinum, their preparation and the pharmaceutical compositions which contain them | LABORATOIRE ROGER BELLON (FR) | 1993-07-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | MEN1 2194/4885GAA 2804/4885KMT2A 1080/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | MEN1 3744/4885GAA 4177/4885KMT2A 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.